DURECT is a biopharmaceutical company that leverages novel epigenetic regulation therapeutics for acute and chronic organ injury. Our unique approach has the potential to make meaningful improvements in patients’ lives and transform human medicine. Larsucosterol (also known as DUR-928), DURECT’s lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes associated with hypermethylation found to be elevated in severe alcohol-associated hepatitis (AH) patients. Larsucosterol is in late-stage clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track Designation. Nonalcoholic steatohepatitis (NASH) is also being explored.
In addition, POSIMIR® (bupivacaine solution) for infiltration use, a nonopioid analgesic utilizing DURECT’s innovative SABER® platform technology, is FDA approved and has been exclusively licensed to Innocoll Pharmaceuticals for development and commercialization in the US. Full Prescribing Information about POSIMIR, including the Boxed Warning, can be found at http://www.posimir.com.